The First Take: Future oral therapies in UC - KOLs speak out

FirstWord's Duncan Emerton - Senior Director of Syndicated Insights and Analysis - and François Pagnini - Lead Analyst - discuss some of the key findings from a new KOL Insight: Ulcerative Colitis report.

New Report - Ulcerative Colitis: KOL Insight

Will oral therapies transform the treatment of ulcerative colitis?

With Pfizer's Xeljanz (tofacitinib) pending approval in the US, new oral therapies are set to transform the ulcerative colitis (UC) treatment landscape. While Pfizer's JAK inhibitor clearly has a head-start, other companies have more selective JAK1-inhibitors in late-stage development, including AbbVie's upadacitinib and Galapagos/Gilead Sciences' filgotinib. Celgene has taken a different approach with its oral molecule, ozanimod. Do KOLs believe they'll all be successful? Other late-stage programmes, including Roche's subcutaneous integrin inhibitor, etrolizumab, and Johnson & Johnson's Stelara (ustekinumab), will also add complexity and choice to the treatment algorithm. How will these products fare in an increasingly competitive environment, where anti-TNF biosimilars look set to dominate? KOLs provide candid insights on these and other new therapies, their likely use, and how they'll affect current mainstays such as anti-TNFs and Takeda's Entyvio (vedolizumab), in KOL Insight: Ulcerative Colitis.

To read more Analyst Notes articles, click here.

Reference Articles